4D Molecular Therapeutics : 4D-310 & 4D-110 Clinical Data Conference Call Presentation

4DMT 4D-310 and 4D-110 Clinical Data Conference Call

October 25, 2021

Legal Disclaimer

This Presentation contains forward looking statements that involve substantial risks and uncertainties.All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our clinical development plans, strategy, future operations, future financial position, prospects, plans, and objectives of management, are forward looking statements.The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words.We may not actually achieve the plans, intentions, or expectations disclosed in these forward looking statements, and you should not place undue reliance on these forward looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward looking statements. In addition, the forward looking statements included in this Presentation represent our views as of the date of this Presentation.We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward looking statements in the future, we specifically disclaim any obligation to do so.These forward looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Presentation.

This Presentation discusses our product candidates that are under preclinical study and in clinical trials, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic use for which they are being studied.

This Presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities.

© 2021 4D Molecular Therapeutics. All Rights Reserved.

2

David Kirn, MD

Co-Founder, Chief Executive Officer

© 2021 4D Molecular Therapeutics. All Rights Reserved.

3

Pipeline

CLINICAL-STAGE, RARE & LARGE PATIENT POPULATIONS

VECTOR

Delivery

R100

Intravitreal

C102

IV

A101

Aerosol

PRODUCT		LEAD					PRODUCT
CANDIDATE	INDICATION	OPTIMIZATION	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3	RIGHTS
OPHTHALMOLOGY
4D-125	XLRP
4D-110	CHM
4D-150	Wet AMD
DME
CARDIOLOGY
4D-310	Fabry
Disease
PULMONOLOGY
4D-710	Cystic
Fibrosis

© 2021 4D Molecular Therapeutics. All Rights Reserved.

4

4D-310 Phase 1/2 Trial:

Initial Clinical Data

© 2021 4D Molecular Therapeutics. All Rights Reserved.

5